A viral post claims that Ethiopian doctors cured a parasitic disease affecting 200 million people with one pill. The evidence points to a more accurate and more compelling story: Ethiopia has made important contributions to schistosomiasis research, while praziquantel provides an effective single-day treatment for many infections, but it is not a universal cure.
The disease shown in the post is most likely schistosomiasis, also known as bilharzia. It is caused by parasitic worms whose larvae enter the body through contact with contaminated freshwater. The infection can damage the intestines, liver, urinary system and reproductive organs, particularly when it remains untreated over time. The figure of 200 million reflects an older estimate. The latest World Health Organization data states that at least 253.7 million people required preventive treatment in 2024. That figure refers to people in endemic areas who require periodic treatment; it should not be interpreted as a confirmed count of active infections in every individual.
Schistosomiasis is closely connected to the conditions in which people live and work. Farmers, fishermen, irrigation workers, women performing domestic tasks in infested water and children who swim or play in rivers and lakes face higher exposure. Once inside the body, the parasite develops in the bloodstream and produces eggs. Some eggs leave the body through urine or faeces, while others become trapped in organs and trigger inflammation and progressive tissue damage. Treatment is therefore only one part of the response. Preventing reinfection requires safer water, improved sanitation, hygiene education and control of the freshwater snails that carry the parasite.
Praziquantel is the medicine at the centre of the claim. It is the WHO-recommended treatment for human schistosomiasis and has been used for decades in both clinical care and mass-treatment programmes. However, “one pill” is an inaccurate description. The treatment is prescribed according to body weight and parasite species. It may involve several tablets or divided doses during a single day, and the outcome can vary according to the intensity and timing of infection. Praziquantel is most effective against adult worms, while reinfection can occur when people remain exposed to contaminated water. In some cases, clinical follow-up or repeat treatment may be necessary. [2]
Ethiopian research demonstrates why the word “cured” must be used carefully. A 2024 study in Amhara Regional State assessed praziquantel among school-aged children infected with Schistosoma mansoni. Using the Kato–Katz stool test, researchers recorded an 88.2 per cent cure rate and a 93.5 per cent reduction in parasite eggs. A urine-based antigen test produced lower cure estimates, ranging from 70.9 to 75.5 per cent, depending on how borderline results were interpreted. Children with heavier infections were less likely to achieve complete clearance, while 23.6 per cent reported at least one mild adverse event. The medicine was effective, but the results were neither absolute nor identical across diagnostic methods.
Ethiopia’s most distinctive scientific contribution to the fight against bilharzia belongs to the late pathologist Aklilu Lemma and his collaborator Legesse Wolde-Yohannes. In 1964, Lemma discovered that the endod plant, also known as soapberry, could kill the freshwater snails responsible for transmitting the parasite. His work targeted the disease at its environmental source rather than treating infected people with a tablet. The discovery created the possibility of a locally available and affordable method of reducing transmission, and Lemma and Wolde-Yohannes received the 1989 Right Livelihood Award for their work. Their contribution was a major African scientific achievement, but it was not the discovery of praziquantel and it was not a single-pill cure.
The strength of praziquantel lies in its ability to support public-health delivery at scale. A low-cost medicine that can be administered through schools and community campaigns gives health authorities a practical means of reducing infection and preventing severe disease. But the real innovation is the system surrounding the medicine: identifying high-risk communities, securing adequate supplies, dosing patients correctly, reaching people consistently and monitoring the results. In 2024, the WHO reported that only 39.6 per cent of people requiring preventive treatment were reached globally. That gap shows why access and implementation remain as important as the medicine itself.
Treatment cannot eliminate schistosomiasis on its own. People may become infected again after returning to unsafe water, while untreated populations can continue the cycle of transmission. The WHO therefore recommends combining periodic treatment with safe drinking water, sanitation, hygiene education, behaviour change and control of the parasite’s snail hosts. This integrated approach turns a successful treatment into a durable public-health intervention. Without it, a single dose may reduce the immediate burden while leaving the conditions for future infection unchanged.
The Ethiopian experience also reveals why evidence must be read in context. A cure rate depends on the parasite species, the patient group, the intensity of infection, the diagnostic method and the timing of follow-up. Reducing the number of parasite eggs is not identical to complete clearance. Relief from symptoms is not the same as eliminating infection. A national campaign treating millions of people is also different from a clinical trial measuring outcomes in a carefully selected group. These distinctions do not weaken the case for praziquantel; they make the case more credible.
For Africa, the strategic opportunity is to move from isolated treatment campaigns towards integrated disease control. That requires reliable procurement, community health workers, school-health systems, laboratory capacity, water infrastructure and data showing where transmission remains concentrated. It also requires financing models that treat prevention as an investment. Preventing chronic infection protects school attendance, productivity and household income while reducing the future cost of advanced treatment.
This is where the story connects to HiPipo Money. Digital finance can support medicine procurement, health-worker payments, community mobilisation, insurance claims, transport and household savings for treatment. It can strengthen the operational infrastructure around public health, especially in communities where distance and cost prevent timely care. But digital platforms must not present approved medicines as self-treatment solutions or promise outcomes that clinical evidence does not support. Financial access is most valuable when it is connected to trusted providers, proper diagnosis and accountable delivery.
The HiPipo Money verdict is clear: Ethiopia has a legitimate and important history of scientific work against schistosomiasis, and praziquantel can treat many infections through a single-day, weight-based regimen. The available evidence does not support the claim that Ethiopian doctors cured 200 million people with one pill. The stronger story is that African science, global medicine and public-health delivery can work together against a disease that continues to affect hundreds of millions of people, but lasting progress depends on treatment, prevention and access advancing together.
